Date |
|
Dec 23, 2014 |
CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments |
Dec 8, 2014 |
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7 More Clinical Sites |
Dec 2, 2014 |
CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold over Same Prior Year Period |
Nov 3, 2014 |
CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial |
Oct 24, 2014 |
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million |
Oct 21, 2014 |
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering |
Oct 21, 2014 |
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants |
Oct 20, 2014 |
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants |
Oct 3, 2014 |
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial |
Sep 29, 2014 |
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients |